KNOWLEDGEABLE ABOUT PHYSIOTHERAPY MANAGEMENT OF MYASTHENIA GRAVIS

Abstract

Acquired myasthenia gravis is an extremely rare illness that now affects about 20 persons in the US for every 1000 births. The hallmark of this autoimmune disease is sporadic muscle weakness that improves with rest and worsens with exertion. For around two thirds of patients, the main symptom is extrinsic ocular muscle involvement. It frequently progresses to include more limb and bulbar muscles, leading to generalized myasthenia gravis. It is well recognized that circulating antibodies against the nicotinic acetylcholine receptor significantly contribute to the aetiology of the condition, even though its exact cause is unknown. The early detection of this ailment is crucial since it is very treatable. Over the past 10 years, there has been a major advancement in our understanding of the condition, leading to new treatment choices and a notable decline in the cause of death and disability.